TCM Biotech International Corp. (TWSE: 4169)
Health Care · Biotechnology · TW
NT$163.00
+6.89% today · +63.0% 1Y
TCM Biotech International Corp. (TWSE: 4169) operates in the Biotechnology industry within the Health Care sector. The company is valued at $302.26M and employs 73 people.
Over the last twelve months the share price has gained 63.0%, trading between 84.50 and 290.00.
Tweenvest scores TCM Biotech International Corp. across four factors: quality 71/100, value 32/100, growth 27/100, dividend 7/100. Its strongest factor is quality.
4169 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $302.26M
- Revenue (TTM)
- $22.05M
- P/E
- —
- EPS
- -0.52
- Dividend yield
- 0.22%
- Beta (5Y)
- 0.13
- 52-week high
- NT$290.00
- 52-week low
- NT$84.50
- Avg volume (3M)
- —
- Shares outstanding
- 59.05M
- Employees
- 73
- Next earnings
- —
About TCM Biotech International Corp.
TCM Biotech International Corp., a biotech company, engages in the research and development of drugs for liver diseases. The company offers medical devices, such as therapy for osteoarthritis, intra-articular implant of hyaluronic acid, automated blood cell separator, absorbable adhesion barrier material, prosthetic and orthotic accessory, and pellefeel mask pressure relief pad; and pharmaceuticals, including iron supplement, therapeutic agent for urinary system, expectorant/mucolytic agent, anticancer drug, antihypertensive drug, and antidiabetic. It also provides medical detection platform for breast cancer recurrent risk detection and postoperative detection platform for liver cancer, as well as philips non-invasive positive pressure ventilation and accessories. TCM Biotech International Corp. was founded in 1998 and is headquartered in New Taipei City, Taiwan.
- ISIN
- TW0004169008
- Founded
- 1998
- Listed since
- Apr 8, 2026
- Exchange
- Taiwan Stock Exchange
- Currency
- TWD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $265.93 | +0.53% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $445.06 | +0.27% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $148.15 | +0.96% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $554.43 | +1.25% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $836.56 | +0.97% |
| argenx SEENXTBR: ARGX | $63.06B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $157.92 | +13.70% |
Figures last refreshed Aug 18, 2026.